Detalles de la búsqueda
1.
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.
Anticancer Drugs
; 35(1): 76-80, 2024 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-37067984
2.
Oral anticancer therapy project: Clinical utility of a specific home care nursing programme on behalf of Italian Association of Medical Oncology (AIOM).
J Clin Nurs
; 29(1-2): 119-129, 2020 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-31532035
3.
Cytidine deaminase enzymatic activity is a prognostic biomarker in gemcitabine/platinum-treated advanced non-small-cell lung cancer: a prospective validation study.
Br J Cancer
; 119(11): 1326-1331, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30405211
4.
Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Lancet Oncol
; 16(3): 257-65, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25704439
5.
Early-Stage Non-Small Cell Lung Cancer: Prevalence of Actionable Alterations in a Monocentric Consecutive Cohort.
Cancers (Basel)
; 16(7)2024 Apr 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-38611088
6.
Clinical utility of Next Generation Sequencing of plasma cell-free DNA for the molecular profiling of patients with NSCLC at diagnosis and disease progression.
Transl Oncol
; 41: 101869, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-38290249
7.
Real-world outcomes of Italian patients with advanced non-squamous lung cancer treated with first-line pembrolizumab plus platinum-pemetrexed.
Eur J Cancer
; 202: 114006, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38489861
8.
Different pathological response and histological features following neoadjuvant chemotherapy or chemo-immunotherapy in resected non-small cell lung cancer.
Front Oncol
; 13: 1115156, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36845706
9.
Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication.
J Immunother
; 46(1): 22-26, 2023 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36472582
10.
Impact of influenza vaccination on survival of patients with advanced cancer receiving immune checkpoint inhibitors (INVIDIa-2): final results of the multicentre, prospective, observational study.
EClinicalMedicine
; 61: 102044, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37434748
11.
Adjuvant chemotherapy of pT1a and pT1b breast carcinoma: results from the NEMESI study.
BMC Cancer
; 12: 158, 2012 Apr 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-22545982
12.
Ribociclib Plus Letrozole in Italian Male Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Case Studies of Phase 3b CompLEEment-1 Trial.
Breast Cancer (Dove Med Press)
; 14: 351-362, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36267663
13.
Pembrolizumab for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer: Analysis of Prognostic Factors of Outcomes.
Anticancer Agents Med Chem
; 22(7): 1278-1285, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-34315390
14.
Randomized phase III trial of adjuvant epirubicin followed by cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) versus CMF followed by epirubicin in patients with node-negative or 1-3 node-positive rapidly proliferating breast cancer.
Breast Cancer Res Treat
; 125(3): 775-84, 2011 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-21132360
15.
Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Tumori
; 96(6): 1010-5, 2010.
Artículo
en Inglés
| MEDLINE | ID: mdl-21388067
16.
Immune-related adverse events correlate with clinical outcomes in NSCLC patients treated with nivolumab: The Italian NSCLC expanded access program.
Lung Cancer
; 140: 59-64, 2020 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31881412
17.
Epidermal growth factor receptor and K-RAS mutations in 411 lung adenocarcinoma: a population-based prospective study.
Oncol Rep
; 22(4): 683-91, 2009 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-19724844
18.
Treatment of metastatic non-small cell lung cancer: 2018 guidelines of the Italian Association of Medical Oncology (AIOM).
Tumori
; 105(5_suppl): 3-14, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31264531
19.
Management of locally advanced non-small cell lung cancer in the modern era: A national Italian survey on diagnosis, treatment and multidisciplinary approach.
PLoS One
; 14(11): e0224027, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31721773
20.
[Cost-effectiveness of oral ibandronate, i.v. zoledronic acid and i.v. generic pamidronate in the management of metastatic bone disease in breast cancer patients: two parallel studies]. / Analisi costo-efficacia di ibandronato orale, acido zoledronico i.v. e pamidronato i.v. nel trattamento della malattia ossea metastatica in pazienti con carcinoma mammario: due studi paralleli.
Recenti Prog Med
; 99(1): 27-31, 2008 Jan.
Artículo
en Italiano
| MEDLINE | ID: mdl-18389868